CMMB — Chemomab Therapeutics Cashflow Statement
0.000.00%
HealthcareSpeculativeMicro CapValue Trap
- $1.27m
- -$31.43m
- 12
- 59
- 17
- 18
Annual cashflow statement for Chemomab Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Net Income/Starting Line | -27.1 | -5.95 | -12.5 | -27.6 |
Depreciation | ||||
Non-Cash Items | 5.73 | 0.324 | 2.23 | 4.12 |
Unusual Items | ||||
Other Non-Cash Items | ||||
Changes in Working Capital | 4.66 | 0.361 | -2.16 | 3.1 |
Change in Accounts Receivable | ||||
Change in Prepaid Expenses | ||||
Change in Other Assets | ||||
Change in Accounts Payable | ||||
Change in Accrued Expenses | ||||
Cash from Operating Activities | -16.5 | -5.24 | -12.4 | -20.4 |
Capital Expenditures | -0.095 | -0.038 | -0.239 | -0.068 |
Purchase of Fixed Assets | ||||
Other Investing Cash Flow Items | 0 | -0.024 | -44.9 | 19.6 |
Sale of Fixed Assets | ||||
Sale/Maturity of Investment | ||||
Purchase of Investments | ||||
Other Investing Cash Flow | ||||
Cash from Investing Activities | -0.095 | -0.062 | -45.2 | 19.5 |
Financing Cash Flow Items | -3.88 | 1.25 | 2.43 | -1.22 |
Other Financing Cash Flow | ||||
Net Issuance / Retirement of Stock | ||||
Cash from Financing Activities | 26.6 | 4.75 | 61.1 | -0.808 |
Beginning Cash Balance | ||||
Ending Cash Balance | ||||
Net Change in Cash | 10.1 | -0.554 | 3.51 | -1.65 |